The Impact of PCSK9 Inhibition in Dyslipidemia Management

Pharmacy Times, April 2017 Respiratory Health, Volume 83, Issue 4

This Continuing Education activity is supported by an educational grant from Amgen.

This activity is supported by an educational grant from Amgen.

The Impact of PCSK9 Inhibition in Dyslipidemia Management

Faculty

Joel C. Marrs, PharmD, FASHP, FCCP, FNLA, BCPS-AQ Cardiology, BCACP, CLS, ASH-CHC Associate ProfessorUniversity of Colorado Skaggs School of Pharmacy and Pharmaceutical SciencesAurora, Colorado

Medical Writing and Editorial Support

Jill Allen, PharmD Drug Information ConsultantPin Oak AssociatesSalt Lake City, Utah

Educational Objectives

After completing this continuing education program, the participant will be able to:

  • Identify the appropriate patient population that will benefit from PCSK9 inhibitors, based on clinical trial data
  • Differentiate the available PCSK9 inhibitors, focusing on their current indications, mechanisms of action, efficacy, safety, and administration
  • Apply strategies to optimize patient outcomes with PCSK9 inhibitors

Target audience: Pharmacists, specialty pharmacists

Type of activity: Application

Release date: April 22, 2017

Expiration date: April 22, 2018

Estimated time to complete activity: 2.0 hours

Fee: Free

Pharmacy Times Continuing Education is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 2.0 contact hours (0.20 CEUs) under the ACPE universal activity number 0290-0000-17-031-H01-P. The activity is available for CE credit through April 22, 2018.